LOCALLY ADVANCED CERVICAL CANCER
Clinical trials for LOCALLY ADVANCED CERVICAL CANCER explained in plain language.
Never miss a new study
Get alerted when new LOCALLY ADVANCED CERVICAL CANCER trials appear
Sign up with your email to follow new studies for LOCALLY ADVANCED CERVICAL CANCER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Immunotherapy combo shows promise in cervical cancer trial
Disease control CompletedThis phase 2 trial tested whether adding the immunotherapy drug atezolizumab to standard chemoradiation helps people with locally advanced cervical cancer. 189 participants received either the combination or standard treatment alone. The goal was to see if the combination delays …
Matched conditions: LOCALLY ADVANCED CERVICAL CANCER
Phase: PHASE2 • Sponsor: Gustave Roussy, Cancer Campus, Grand Paris • Aim: Disease control
Last updated Jun 27, 2026 12:03 UTC
-
Immunotherapy boosts standard treatment for advanced cervical cancer
Disease control CompletedThis study tested whether adding the immunotherapy drug pembrolizumab to standard chemoradiation helps people with high-risk, locally advanced cervical cancer live longer without their cancer growing. About 1,060 participants received either pembrolizumab or a placebo alongside t…
Matched conditions: LOCALLY ADVANCED CERVICAL CANCER
Phase: PHASE3 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Jun 27, 2026 09:07 UTC
-
Immunotherapy combo shows promise in cervical cancer trial
Disease control CompletedThis early-phase study tested whether adding the immunotherapy drug nivolumab to standard chemoradiation is safe for people with locally advanced cervical cancer. Twenty-one adults received nivolumab alongside cisplatin and radiation, followed by up to six months of nivolumab alo…
Matched conditions: LOCALLY ADVANCED CERVICAL CANCER
Phase: PHASE1, PHASE2 • Sponsor: Institut Curie • Aim: Disease control
Last updated Jun 26, 2026 19:18 UTC